This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch. Active years: 2019-2025.
Company Filing History:
Years Active: 2019-2025
Title: Matthias Obenaus: Innovator in Cancer Immunotherapy
Introduction
Matthias Obenaus is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of cancer immunotherapy, particularly through his innovative patents. With a total of 3 patents, his work focuses on high avidity antigen recognizing constructs that have the potential to revolutionize cancer treatment.
Latest Patents
Obenaus's latest patents include groundbreaking inventions related to high avidity antigen recognizing constructs. These constructs, such as antibodies or T cell receptors, specifically bind to the melanoma-associated antigen (MAGE) A1. They are particularly useful for the diagnosis, prevention, or therapy of tumorous diseases characterized by the specific expression of the MAGE-A1 antigen. Additionally, his inventions provide nucleic acids, vectors, and host cells, such as CD4 or CD8 positive T cells, which encode, comprise, or present these antigen recognizing constructs. This innovative approach offers new avenues for immune therapy, specifically adoptive T cell therapy, in treating cancer.
Career Highlights
Throughout his career, Matthias Obenaus has worked with esteemed institutions, including the Max Delbrück Center for Molecular Medicine in Berlin-Buch. His research has significantly advanced the understanding and treatment of cancer, particularly through the development of novel therapeutic constructs.
Collaborations
Obenaus has collaborated with notable colleagues in his field, including Thomas Blankenstein and Catarina Leitão. These partnerships have further enriched his research and contributed to the advancement of cancer immunotherapy.
Conclusion
Matthias Obenaus stands out as an influential inventor in the realm of cancer treatment. His innovative patents and collaborative efforts continue to pave the way for advancements in immunotherapy.